p450 - publications

Predict more p450 - ligand interactions now!

1. Clin Transl Oncol. 2012 Feb;14(2):157-9.

CYP2D6*4 allele and breast cancer risk: Is there any association?

Fernández-Santander A, Del Saz Sánchez M, Tejerina Gómez A, Bandrés Moya F.

Departamento de Ciencias Biomédicas Básicas, Facultad de Ciencias Biomédicas,
Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.

Background CYP2D6 is an important cytochrome P450 enzyme. These enzymes catalyse
the oxidative biotransformation of about 25% of clinically important drugs as
well as the metabolism of numerous environmental chemical carcinogens. The most
frequent null allele of CYP2D6 in European populations, CYP2D6*4, has been
studied here in order to elucidate whether a relationship exists between this
allele and the risk of developing breast cancer in a Spanish population.
Materials and methods Ninety-six breast cancer Spanish patients and one hundred
healthy female volunteers were genotyped for the CYP2D6*4 allele using AmpliChip
CYP450 Test technology. Results Homozygous CYP2D6*4 frequency was significant
lower in breast cancer patients than in the control group (OR=0.22, p=0.04). The
heterozygous CYP2D6*4 group also displayed lower values in patients than in
controls but the difference was not significant (OR=0.698, p=0.28). Therefore,
the presence of the CYP2D6*4 allele seems to decrease susceptibility to breast
carcinoma in the selected population. Conclusions A possible decreased
transformation of procarcinogens by CYP2D6*4 poor metabolisers could result in a
protective effect against carcinogens.

PMID: 22301406 [PubMed - in process]